top of page

Duopharma Biotech Partners with The Live Green Co to Pave the Way for Plant-Based Pharmaceuticals


Duopharma Biotech Bhd (DBB) has taken a significant step towards the future of pharmaceuticals with its investment of up to US$1 million in The Live Green Co (TLGC), a US-based biotech company. This strategic partnership aims to explore the application of plant ingredients and cutting-edge technology to replace animal, synthetic, and ultra-processed components in pharmaceutical products.


The investment will allow DBB to acquire shares in TLGC, granting the company exclusive manufacturing, marketing, and distribution rights for jointly developed products in the ASEAN region. This decision comes in the wake of a collaboration agreement signed between DBB and TLGC in 2022, solidifying their commitment to revolutionizing the pharmaceutical industry.


Leonard Ariff Abdul Shatar, DBB's group managing director, highlighted the company's focus on its consumer healthcare segment, expressing enthusiasm for the investment. He noted that TLGC's innovative solutions, such as Charaka and Precision Fermentation, have become even more relevant in today's market, making the expanded commitment and partnership timely and strategic.


Charaka, TLGC's proprietary AI-enabled search engine and discovery platform, will be a game-changer for DBB. The platform plays a crucial role in researching and developing plant-based alternatives to animal, artificial, and ultra-processed food ingredients. With access to Charaka, DBB is set to expand its product offerings into wellness and functional foods, positioning itself at the forefront of the plant-based pharmaceutical movement.


The collaboration between DBB and TLGC will yield tangible results, as at least two reformulated products are expected to enter the market by the fourth quarter of 2024. This marks a significant milestone for both companies, as they pave the way for a more sustainable and plant-based future in the pharmaceutical industry.


DBB's leading consumer brands, including Flavettes, Champs, Proviton, Uphamol, and Naturalle, will now be positioned to target plant-based products. As consumers increasingly seek healthier and more environmentally friendly options, this strategic move by DBB and TLGC aligns perfectly with the growing demand for plant-based alternatives in the pharmaceutical sector.


The investment by DBB in TLGC not only represents a commitment to innovation but also a shared vision of a greener and more sustainable future. By harnessing the power of plant-based ingredients and cutting-edge technology, these two pioneering companies are taking a bold step towards transforming the pharmaceutical landscape and revolutionizing the way we approach healthcare. As the partnership continues to bear fruit, the global community eagerly awaits the positive impact of their collaborative efforts in shaping a healthier and more eco-friendly tomorrow.

Commenti

Valutazione 0 stelle su 5.
Non ci sono ancora valutazioni

Aggiungi una valutazione
bottom of page